Verismo Therapeutics Expands KIR-CAR Solid Tumor Treatment Pipeline with Novel Binder Developed at Penn Targeting Claudin 6 (CLDN6)
Verismo's KIR-CAR pipeline now spans two solid tumor antigens: mesothelin, targeted by the clinical-stage SynKIR™-110 in the STAR-101 Phase 1 trial, and CLDN6, targeted by a new preclinical program Second binder discovered in collaboration with University of Pennsylvania, following the...
Verismo's KIR-CAR pipeline now spans two solid tumor antigens: mesothelin, targeted by the clinical-stage SynKIR™-110 in the STAR-101 Phase 1 trial, and CLDN6, targeted by a new preclinical program Second binder discovered in collaboration with University of Pennsylvania, following the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.